Baird raised the firm’s price target on CVS Health (CVS) to $92 from $82 and keeps an Outperform rating on the shares. The firm updated its model and believes its bull thesis remains intact.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $93 from $89 at Morgan Stanley
- CVS Health price target raised to $101 from $99 at Piper Sandler
- CVS Health price target raised to $93 from $87 at Barclays
- CVS Health price target raised to $97 from $96 at UBS
- CVS Health: Strong Financial Outlook and Strategic Initiatives Drive Buy Rating